Vertex Pharmaceuticals Incorporated (FRA:VX1)

Market Cap	100.35B -5.5%
Revenue (ttm)	9.99B +10.3%
Net Income	3.13B
EPS	12.12
Shares Out	n/a
PE Ratio	32.04
Forward PE	23.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75
Average Volume	80
Open	394.25
Previous Close	404.00
Day's Range	394.25 - 399.25
52-Week Range	313.75 - 475.95
Beta	n/a
RSI	53.83
Earnings Date	Feb 12, 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 6,100
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: VX1

Financial Performance

Financial numbers in USD